Galecto Seeks Shareholder Nod for Cayman Move, Stock Issuance

Ticker: DMRA · Form: DEF 14A · Filed: Dec 31, 2025 · CIK: 1800315

Sentiment: mixed

Topics: Corporate Governance, Shareholder Meeting, Stock Authorization, Redomestication, Equity Incentive Plan, Employee Stock Purchase Plan, Dilution Risk

Related Tickers: DMRA

TL;DR

**Galecto's move to the Cayman Islands and massive share authorization is a clear play for financial flexibility and executive protection, but watch out for potential dilution.**

AI Summary

Galecto, Inc. (DMRA) is seeking stockholder approval for six key proposals at a Special Meeting on February 9, 2026, including the issuance of common stock upon conversion of Series B and Series C Preferred Stock, an increase in authorized common stock from 300,000,000 to 500,000,000 shares, and a redomestication from Delaware to the Cayman Islands. The company also seeks approval for the Galecto, Inc. 2026 Equity Incentive Plan and the Galecto, Inc. 2026 Employee Stock Purchase Plan. The redomestication is expected to result in substantial savings by eliminating annual Delaware franchise tax and potentially reducing litigation risk for directors and officers. As of December 29, 2025, there were 1,597,321 shares of Common Stock outstanding, with 265,309 shares from the Asset Acquisition ineligible to vote on Proposal No. 1 for Nasdaq listing rule purposes. The Board of Directors recommends a 'FOR' vote on all proposals, emphasizing the strategic benefits for the company and its stockholders.

Why It Matters

Galecto's proposed redomestication to the Cayman Islands could significantly impact its financial structure by eliminating Delaware franchise taxes, potentially boosting profitability and investor returns. The increase in authorized shares and new equity incentive plans are crucial for future capital raises and employee retention, directly affecting the company's ability to fund its pipeline and compete for talent in the biotech sector. For investors, these changes represent a strategic shift that could alter governance, legal protections, and the dilution landscape, making a careful review of the proposals essential for understanding long-term value.

Risk Assessment

Risk Level: medium — The redomestication to the Cayman Islands, while potentially saving on Delaware franchise tax, shifts governance to a jurisdiction with different legal protections for shareholders, as detailed in 'Comparison of Rights of Holders of the Delaware Corporation Capital Stock and the Cayman Company Share Capital' on page 104. The proposed increase in authorized common stock from 300,000,000 to 500,000,000 shares, alongside the issuance of shares for Series B and Series C Preferred Stock conversion, presents a significant risk of future dilution for existing common stockholders.

Analyst Insight

Investors should vote 'FOR' the redomestication if they prioritize potential tax savings and enhanced director/officer protection, but carefully consider the dilution implications of the increased authorized shares. Engage with Galecto's investor relations for clarity on the specific use of the additional 200,000,000 authorized shares.

Financial Highlights

debt To Equity
N/A
revenue
$0.00
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
N/A
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is the purpose of Galecto, Inc.'s Special Meeting on February 9, 2026?

Galecto, Inc.'s Special Meeting on February 9, 2026, is being held to approve six key proposals, including the issuance of common stock upon conversion of Series B and Series C Preferred Stock, an increase in authorized common stock from 300,000,000 to 500,000,000 shares, and the redomestication of the company from Delaware to the Cayman Islands.

Why is Galecto, Inc. proposing to redomesticate to the Cayman Islands?

Galecto, Inc. is proposing the redomestication to the Cayman Islands primarily to eliminate its obligation to pay the annual Delaware franchise tax, which is expected to result in substantial long-term savings. Additionally, the move aims to attract and retain qualified management by potentially reducing the risk of lawsuits against the company and its directors and officers, as Cayman Islands law may offer greater protection.

How will the proposed increase in authorized shares affect Galecto, Inc. stockholders?

The proposed increase in authorized shares of Common Stock from 300,000,000 to 500,000,000 could lead to potential dilution for existing stockholders if the new shares are issued. This increase provides Galecto, Inc. with greater flexibility for future capital raises, strategic transactions, or equity compensation plans.

What is the record date for voting at Galecto, Inc.'s Special Meeting?

The record date for determining stockholders entitled to vote at Galecto, Inc.'s Special Meeting is the close of business on December 29, 2025. Only stockholders of record on this date will be eligible to cast votes on the proposals.

Are all outstanding shares of Galecto, Inc. Common Stock eligible to vote on all proposals?

No, while there were 1,597,321 shares of Common Stock outstanding on the record date, 265,309 shares issued in the Asset Acquisition are not entitled to vote on Proposal No. 1 (Conversion Proposal) for purposes of Nasdaq listing rules. These shares will be subtracted in a separate tabulation to ensure compliance with Nasdaq requirements.

What are the U.S. federal income tax implications for Galecto, Inc. stockholders regarding the Cayman Redomestication?

Galecto, Inc. intends for the Cayman Redomestication to qualify as a 'reorganization' under Section 368(a) of the Internal Revenue Code. If it qualifies, a U.S. Holder of Galecto stock will generally not recognize gain or loss upon the redomestication, as detailed in the 'U.S. Federal Income Tax Considerations of the Cayman Redomestication' section of the proxy statement.

What are the new equity plans Galecto, Inc. is seeking approval for?

Galecto, Inc. is seeking approval for two new equity plans: the Galecto, Inc. 2026 Equity Incentive Plan (Proposal No. 4) and the Galecto, Inc. 2026 Employee Stock Purchase Plan (Proposal No. 5). These plans are designed to attract, retain, and motivate employees and directors.

How can Galecto, Inc. stockholders vote at the Special Meeting?

Galecto, Inc. stockholders can vote over the Internet, by telephone, by mail using the enclosed proxy card, or by voting during the virtual Special Meeting at www.virtualshareholdermeeting.com/GLTO2026SM. Instructions are provided on the proxy card or by their broker for 'street name' holders.

What is the Board of Directors' recommendation for the proposals?

The Board of Directors of Galecto, Inc. has approved all six proposals and determined them to be advisable, fair, and in the best interests of Galecto's stockholders. Accordingly, the Board recommends that stockholders vote 'FOR' each of the proposals.

What are the key differences in stockholder rights between Delaware and Cayman Islands law for Galecto, Inc.?

As a result of the Cayman Redomestication, Galecto, Inc. stockholders' rights will transition from being governed by Delaware law to Cayman Islands law and the new memorandum and articles of association. These differences are summarized in the proxy statement under 'Comparison of Rights of Holders of the Delaware Corporation Capital Stock and the Cayman Company Share Capital' beginning on page 104.

Risk Factors

Industry Context

Galecto operates in the highly competitive biotechnology sector, focusing on developing novel therapies for fibrotic diseases and cancer. The industry is characterized by long development cycles, significant R&D investment, and reliance on clinical trial success and regulatory approvals. Companies often pursue strategic partnerships or financing rounds to fund their pipeline development.

Regulatory Implications

The proposed redomestication to the Cayman Islands may introduce new regulatory considerations and compliance requirements. Furthermore, the company must continue to adhere to Nasdaq listing rules, including those related to minimum bid price and shareholder equity, to maintain its listing.

What Investors Should Do

  1. Vote 'FOR' Proposal No. 1 to approve the conversion of Series B and Series C Preferred Stock, which is necessary for potential future financing and strategic flexibility.
  2. Vote 'FOR' Proposal No. 2 to increase the authorized shares of common stock to 500,000,000, enabling future equity issuances for funding and strategic initiatives.
  3. Vote 'FOR' Proposal No. 3 to approve the redomestication to the Cayman Islands, which is expected to reduce administrative costs and potential litigation risks.
  4. Vote 'FOR' Proposal No. 4 to approve the 2026 Equity Incentive Plan, crucial for attracting and retaining talent in the competitive biotech landscape.
  5. Vote 'FOR' Proposal No. 5 to approve the 2026 Employee Stock Purchase Plan, offering employees an opportunity to invest in the company's future.

Key Dates

Glossary

DEF 14A
A proxy statement filing required by the U.S. Securities and Exchange Commission (SEC) for companies holding annual or special meetings of shareholders. (This document contains the information and proposals being presented to Galecto's shareholders for a vote.)
Redomestication
The process of changing a company's legal domicile from one jurisdiction to another. (Galecto is proposing to move its incorporation from Delaware to the Cayman Islands to potentially reduce costs and litigation risk.)
Series B Preferred Stock
A class of preferred stock issued by Galecto that is subject to conversion into common stock. (Approval is sought to convert these shares, which will impact the company's capital structure and potentially dilute common stockholders.)
Series C Preferred Stock
Another class of preferred stock issued by Galecto that is subject to conversion into common stock. (Similar to Series B, approval is needed for their conversion into common stock.)
Equity Incentive Plan
A plan that allows a company to grant stock options, restricted stock units, or other equity-based awards to employees and directors. (Galecto is seeking approval for its 2026 Equity Incentive Plan to incentivize and retain key personnel.)
Employee Stock Purchase Plan
A plan that allows employees to purchase company stock, often at a discount, through payroll deductions. (Galecto is seeking approval for its 2026 Employee Stock Purchase Plan to allow employees to invest in the company.)
Par Value
A nominal value assigned to a share of stock, typically very low, used for accounting purposes. (The par value for Galecto's common and preferred stock is $0.00001 per share.)

Year-Over-Year Comparison

This DEF 14A filing focuses on key corporate actions and proposals for an upcoming special meeting, rather than a comprehensive financial review of the past year. Therefore, direct year-over-year comparisons of financial metrics like revenue or net income are not applicable in this context. The filing highlights proposed changes to the company's capital structure and corporate domicile, which are strategic decisions rather than performance indicators.

Filing Stats: 4,879 words · 20 min read · ~16 pages · Grade level 10.3 · Accepted 2025-12-31 16:17:30

Key Financial Figures

Filing Documents

Risk Factors

Risk Factors 15 Description of Business 56 Proposals 96 Proposal No. 1: Approval of Conversion Proposal 96 Proposal No. 2: Approval of Amendment of the Certificate of Incorporation 99 Proposal No. 3: Approval of Redomestication of the Company 101 Proposal No. 4: Approval of the Galecto, Inc. 2026 Equity Incentive Plan 130 Proposal No. 5: Approval of the Galecto, Inc. 2026 Employee Stock Purchase Plan 134 Proposal No. 6: Approval of Adjournment Proposal 138 Other Information 139 Executive Officer Compensation 139 Director Compensation 145

Description of Capital Stock

Description of Capital Stock 148 Principal Stockholders 153 Where You Can Find Additional Information 155 Householding 155 Stockholder Proposals 156 Information Incorporated by Reference 157 Other Matters 158 Annexes Annex A – Certificate of Amendment to Certificate of Incorporation A-1 Annex B – Plan of Conversion B-1 Annex C – Form of Cayman Islands Memorandum and Articles of Association C-1 Annex D – Resolutions of the Board of Directors for the Cayman Redomestication D-1 Annex E-1 – Cayman Islands Series A Certificate of Designation E-1-1 Annex E-2 – Cayman Islands Series B Certificate of Designation E-2-1 Annex E-3 – Cayman Islands Series C Certificate of Designation E-3-1 Annex F – Certificate of Incorporation F-1 Annex G – Bylaws G-1 Annex H-1 – Delaware Series A Certificate of Designation H-1-1 Annex H-2 – Delaware Series B Certificate of Designation H-2-1 Annex H-3 – Delaware Series C Certificate of Designation H-3-1 Annex I – Galecto, Inc. 2026 Equity Incentive Plan I-1 Annex J – Galecto, Inc. 2026 Employee Stock Purchase Plan J-1 Annex K – Form of Galecto Proxy Card K-1 iv TABLE OF CONTENTS GALECTO, INC. Ole Maaloes Vej 3 DK-2200 Copenhagen N Denmark 75 State Street Suite 100 Boston, MA 02109 (+45) 70 70 52 10 PROXY STATEMENT SPECIAL MEETING OF STOCKHOLDERS To Be Held on February 9, 2026 INFORMATION CONCERNING SOLICITATION AND VOTING This proxy statement contains information about the Special Meeting of Stockholders of Galecto, Inc. (the "Special Meeting"), which will be held virtually, via live webcast at www.virtualshareholdermeeting.com/GLTO2026SM on February 9, 2026 at 9:00 a.m. Eastern Time. The board of directors of Galecto, Inc. (the "Board of Directors") is using this proxy statement to solicit proxies for use at the Special Meeting. In this proxy statement, the terms "Galecto," "the Company," "we," "us," and "our" refer to Galecto, Inc. The

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing